PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia

Journal of Clinical Investigation

Volumn 126, Issue 1, 2016, Pages 85-98

  Cole, Christopher B ^a   Verdoni, Angela M ^a   Ketkar, Shamika ^a   Leight, Elizabeth R ^a   Russler Germain, David A ^a   Lamprecht, Tamara L ^a   Demeter, Ryan T ^b   Magrini, Vincent ^b   Ley, Timothy J ^a,b  

^a Division of Oncology   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AF9 PROTEIN; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; MIXED LINEAGE LEUKEMIA PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN; RETINOIC ACID RECEPTOR ALPHA; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX1T1; UNCLASSIFIED DRUG; DNA (CYTOSINE 5) METHYLTRANSFERASE; MLL-AF9 FUSION PROTEIN, MOUSE; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; RUNX1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL SELF-RENEWAL; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; ENZYME ACTIVITY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; LOSS OF FUNCTION MUTATION; MOLECULAR PATHOLOGY; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REGULATORY DNA SEQUENCE; ANIMAL; C57BL MOUSE; LEUKEMIA, PROMYELOCYTIC, ACUTE; PHYSIOLOGY;

ANIMALS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, FUSION;

EID: 84956674141     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI82897     Document Type: Article

References (51)

1. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074.
2. Ley T, Ding L, Walter M. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010; 363(25):2424-2433.
3. Challen GA, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2012;44(1):23-31.
4. Yang L, Rau R, Goodell MA. DNMT3A in haematological malignancies. Nat Rev Cancer. 2015;15(3):152-165.
5. Challen GA, et al. Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells. Cell Stem Cell. 2014;15(3):350-364.
6. Russler-Germain DA, et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell. 2014;25(4):442-454.
7. Kim SJ, Zhao H, Hardikar S, Singh AK, Goodell MA, Chen T. A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood. 2013;122(25):4086-4089.
8. Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ. Altered myeloid development and acute leukemia in transgenic mice expressing PMLRARα under control of cathepsin G regulatory sequences. Blood. 1997;89(2):376-387.
9. Brown D, et al. A PML-RARα transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 1997;94(6):2551-2556.
10. He LZ, et al. Acute leukemia with promyelocytic features in PML/RARα transgenic mice. Proc Natl Acad Sci U S A. 1997;94(10):5302-5307.
11. Kogan SC. Mouse models of acute promyelocytic leukemia. Curr Top Microbiol Immunol. 2007;313:3-29.
12. Westervelt P, et al. High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARα expression. Blood. 2003;102(5):1857-1865.
13. Minucci S, et al. PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood. 2002;100(8):2989-2995.
14. Kamashev D, Vitoux D, De Thé H. PMLRARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J Exp Med. 2004;199(8):1163-1174.
15. Subramanyam D, et al. PML-RARα and Dnmt3a1 cooperate in vivo to promote acute promyelocytic leukemia. Cancer Res. 2010;70(21):8792-8801.
16. Hong SH, David G, Wong CW, Dejean A, Privalsky ML. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARα) and PLZF-RARα oncoproteins associated with acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 1997;94(17):9028-9033.
17. Villa R, et al. The methyl-CpG binding protein MBD1 is required for PML-RARα function. Proc Natl Acad Sci U S A. 2006;103(5):1400-1405.
18. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 1998;391(6669):811-814.
19. Fazi F, et al. Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo. Oncogene. 2005;24(11):1820-1830.
20. Datta J, et al. Physical and functional interaction of DNA methyltransferase 3A with Mbd3 and Brg1 in mouse lymphosarcoma cells. Cancer Res. 2005;65(23):10891-10900.
21. Morey L, et al. MBD3, a component of the NuRD complex, facilitates chromatin alteration and deposition of epigenetic marks. Mol Cell Biol. 2008;28(19):5912-5923.
22. Boukarabila H, et al. The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. Genes Dev. 2009;23(10):1195-1206.
23. Villa R, et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell. 2007;11(6):513-525.
24. Di Croce L, et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science. 2002;295(5557):1079-1082.
25. Martens JH, et al. PML-RARα/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell. 2010;17(2):173-185.
26. Wang K, et al. PML/RARα targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia. Cancer Cell. 2010;17(2):186-197.
27. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99(3):247-257.
28. Jeong M, et al. Large conserved domains of low DNA methylation maintained by Dnmt3a. Nat Genet. 2014;46(1):17-23.
29. Steffen B, et al. AML1/ETO induces self-renewal in hematopoietic progenitor cells via the Groucho-related amino-terminal AES protein. Blood. 2011;117(16):4328-4337.
30. Chen W, et al. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell. 2008;13(5):432-440.
31. Wartman LD, et al. Expression and function of PML-RARA in the hematopoietic progenitor cells of Ctsg-PML-RARA mice. PLoS One. 2012;7(10):e46529.
32. Jurkowska RZ, Jurkowski TP, Jeltsch A. Structure and function of mammalian DNA methyltransferases. Chembiochem. 2011;12(2):206-222.
33. Li H, Rauch T, Chen ZX, Szabó PE, Riggs AD, Pfeifer GP. The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells. J Biol Chem. 2006;281(28):19489-19500.
34. Wienholz BL, Kareta MS, Moarefi AH, Gordon CA, Ginno PA, Chédin F. DNMT3L modulates significant and distinct flanking sequence preference for DNA methylation by DNMT3A and DNMT3B in vivo. PLoS Genet. 2010;6(9):e1001106.
35. Jin B, et al. Linking DNA methyltransferases to epigenetic marks and nucleosome structure genome-wide in human tumor cells. Cell Rep. 2012;2(5):1411-1424.
36. Dodge JE, et al. Inactivation of Dnmt3b in mouse embryonic fibroblasts results in DNA hypomethylation, chromosomal instability, and spontaneous immortalization. J Biol Chem. 2005;280(18):17986-17991.
37. Georgiades P, et al. VavCre transgenic mice: A tool for mutagenesis in hematopoietic and endothelial lineages. Genesis. 2002;34(4):251-256.
38. Dodge JE, et al. Inactivation of Dnmt3b in mouse embryonic fibroblasts results in DNA hypomethylation, chromosomal instability, and spontaneous immortalization. J Biol Chem. 2005; 280(18):17986-17991.
39. Welch JS, Yuan W, Ley TJ. PML-RARA can increase hematopoietic self-renewal without causing a myeloproliferative disease in mice. J Clin Invest. 2011;121(4):1636-1645.
40. Mayle A, et al. Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood. 2015;125(4):629-638.
41. Wojiski S, et al. PML-RARα initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors. Leukemia. 2009;23(8):1462-1471.
42. Trowbridge JJ, Snow JW, Kim J, Orkin SH. DNA methyltransferase 1 is essential for and uniquely regulates hematopoietic stem and progenitor cells. Cell Stem Cell. 2009;5(4):442-449.
43. Trowbridge JJ, Sinha AU, Zhu N, Li M, Armstrong SA, Orkin SH. Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev. 2012;26(4):344-349.
44. Liu S, et al. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res. 2005;65(4):1277-1284.
45. Lasa A, et al. MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias. Leukemia. 2004;18(7):1231-1237.
46. Schoofs T, et al. DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor binding. Blood. 2013;121(1):178-187.
47. Rohde C, Schoofs T, Müller-Tidow C. The limited contribution of DNA methylation to PML-RARα induced leukemia. Oncotarget. 2013;4(1):5-6.
48. Oka M, Rodić N, Graddy J, Chang LJ, Terada N. CpG sites preferentially methylated by Dnmt3a in vivo. J Biol Chem. 2006;281(15):9901-9908.
49. Morse HC 3rd, et al. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood. 2002;100(1):246-258.
50. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19(2):185-193.
51. Irizarry RA, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249-264.